We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
The most recent trading session ended with Recursion Pharmaceuticals (RXRX - Free Report) standing at $6.11, reflecting a -0.97% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.01% gain on the day. Elsewhere, the Dow gained 0.09%, while the tech-heavy Nasdaq added 0.08%.
Heading into today, shares of the biotechnology company had gained 1.65% over the past month, outpacing the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21% in that time.
The investment community will be paying close attention to the earnings performance of Recursion Pharmaceuticals in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.31, reflecting a 27.91% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $30.31 million, up 187.83% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.58 per share and revenue of $70.63 million, which would represent changes of 0% and +58.45%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Recursion Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.72% increase. Recursion Pharmaceuticals is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow RXRX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
The most recent trading session ended with Recursion Pharmaceuticals (RXRX - Free Report) standing at $6.11, reflecting a -0.97% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.01% gain on the day. Elsewhere, the Dow gained 0.09%, while the tech-heavy Nasdaq added 0.08%.
Heading into today, shares of the biotechnology company had gained 1.65% over the past month, outpacing the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21% in that time.
The investment community will be paying close attention to the earnings performance of Recursion Pharmaceuticals in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.31, reflecting a 27.91% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $30.31 million, up 187.83% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.58 per share and revenue of $70.63 million, which would represent changes of 0% and +58.45%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Recursion Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.72% increase. Recursion Pharmaceuticals is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow RXRX in the coming trading sessions, be sure to utilize Zacks.com.